Fig. 2: The potential novel RTK candidate EphA2 for the modulation of drug resistance identified via quantitative MS. | Experimental & Molecular Medicine

Fig. 2: The potential novel RTK candidate EphA2 for the modulation of drug resistance identified via quantitative MS.

From: Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells

Fig. 2

a The quantified MS spectra of the identified SILAC-labeled phosphopeptide of EphA2 are shown. b MS/MS spectra of the corresponding identified phosphopeptide of EphA2. c Validation of the change in the identified phosphorylation site of EphA2 between HuH-7 and HuH-7R cells via western blotting. The identified peptide sequence, phosphorylated residue, and quantified ratio are presented. EPHA2 ephrin type A receptor 2.

Back to article page